High-Content Biology Platform

The High Content Biology Platform lab employ high-throughput screening technologies as a means to identify novel components that modify cellular signal transduction pathways and autophagy

13 January 2020

They are developing novel screening technologies based on arrayed CRISPR libraries and using knockout cell panels, where their studies will generate strategies for the identification of potential therapeutic targets in diseases such as cancer and neuro-degeneration. Robin Ketteler's initiative has the resources and expertise to translate these basic research findings into a drug discovery program to identify potential therapeutic lead compounds.

Visit the High Content Biology Platform website

The UCL TRO Drug Discovery Group support Small Molecule projects

'As an academic biochemist with an interest in early stage drug discovery, we always face a bottleneck in taking any of the chemical hit matter forward for further development. The TRO Drug Discovery group is very collaborative and has been very helpful to develop chemistry around our hit compounds that has opened up several lines of new research and exciting drug development opportunities.' - Professor Robin Ketteler, Professor of Translational Cell Biology